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Abstract Juvenile dermatomyositis (JDM) is a multi-
system disease characterized by non-purulent inflammation
in the striated muscle and skin. Banker-type JDM is diffi-
cult to treat and control, especially when it is a form that is
resistant to steroid treatment. Here, we report a 2-year-old
girl with Banker-type JDM resistant to steroid treatment.
The patient received intravenous immunoglobulin (IVIg) at
400 mg/kg/5 days a week every 6 weeks. Motor function
improved and the patient was able to walk after six cycles.
IVIg was administered every four weeks for six cycles
thereafter, and the patient was able to walk more quickly
with an improvement in quality of life. No apparent
adverse effects were observed during IVIg treatment.
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Introduction
Juvenile dermatomyositis (JDM) is an idiopathic, multi-
system, collagen disease characterized by non-purulent
inflammation in the striated muscle and skin. Clinical
pathology differs from that of the adult type; there is a
lower frequency of malignant tumors and many cases
respond well to steroids. Clinically, JDM can be classified
into three subtypes: Banker, Brunsting, and fulminant [1].
There is no established therapy for steroid-resistant
Banker-type JDM, and symptoms are very difficult to
control [1]. In the following case report, long-term, high-
dose therapy, with intravenous immunoglobulin (IVIg),
was performed in a 2-year-old girl with steroid-resistant,
Banker-type JDM. This is the first reported case of IVIg
treatment in a child as young as 2 years old.
Case report
A 2-year-old girl was brought to the hospital because of a
waddling gait with intermittent claudication. In addition,
she was not able to stand on one leg. Manual muscle testing
(MMT) of the deltoid and quadriceps femoris resulted in a
grade of three, showing muscle weakness predominantly in
the proximal muscles. Also, Gower’s sign was positive.
Muscle tonus did not restrict the range of motion of joints,
and muscle mass was normal, but the gastrocnemius was
hard and painful to the touch. Erythema and heliotrope-like
exanthema were noted in the forehead. Upon neurophysi-
ological examination, motor and sensory nerves were
deemed normal. Muscle CT showed partial fatty degener-
ation in the gastrocnemius. Blood test results were as fol-
lows: creatine phosphokinase (CPK) = 14,420 IU/l;
myoglobin = 777 ng/ml; aspartate aminotransferase
(AST) = 211 IU/l; antinuclear antibodies (ANA) = 5,120
times; and negative for the Jo-1 antibody. Upon biceps
brachii muscle biopsy, necrosis, regeneration and irregular
sized myofibers, and angitis accompanied by perivascular
lymphocyte infiltration were noted. JDM was diagnosed
based on various tests and the clinical course.
After the initial oral prednisolone (PSL) dose at 2 mg/
kg/day, CPK decreased to about 1,000 IU/l after
1.5 months; however, glaucoma developed after several
months. Dual-energy X-ray absorptiometry index was 0.3.
The PSL dose was gradually reduced, and CPK increased
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to more than 8,000 when the dose was reduced to 1 mg/kg/
day, indicating recurrence of condition. Clinically, the
patient became unable to turn over in bed or move her legs
against gravity. Muscle MRI showed fatty degeneration
and atrophic changes predominantly in the gastrocnemius.
Administration of IVIg at 400 mg/kg/5 days every
6 weeks was initiated, and CPK levels stabilized between
4,000 and 5,000 IU/l. Although CPK did not decrease,
motor function improved and the patient became able to
walk after six cycles. IVIg was administered every four
weeks for six cycles thereafter, and the patient was able to
walk more quickly with an improvement in her quality of
life. No apparent adverse effects were noted during IVIg
treatment.
Discussion
In the present case, standard steroid treatment initially
exhibited an effect but the disease recurred during steroid
tapering therapy. Thus, a 12-cycle long-term, high-dose
IVIg was performed every 6 weeks for the first six cycles
and every 4 weeks for the subsequent six cycles, focusing
on immunological abnormalities in juvenile dermatomyo-
sitis. In our case, IVIg therapy resulted in clinical
improvement in the patient’s muscle weakness. Subse-
quently, quality of life improved such that the patient was
able to walk unassisted. No apparent adverse effects were
noted during the course of IVIg therapy. IVIg therapy has
recently been reported to be effective in the treatment of
steroid-resistant JDM [1, 2]. In a retrospective analysis by
Lam et al. [3] regarding IVIg therapy in patients with poor
response to first-line corticosteroid therapy, it was found
that IVIG may be effective in controlling JDM symptoms.
However, no consensus has yet been reached on IVIg
dosing intervals and doses. Interestingly, the patient’s daily
physical activity levels increased with every 4 weeks of
IVIg therapy. To date, long-term IVIg therapy for steroid-
resistant JDM in a patient as young as two years of age has
never been reported. Although the results of hematology in
this case indicated that complete remission could not be
realized, the results did suggest that IVIg therapy is useful
for controlling steroid-resistant fulminant JDM in young
children.
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